Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

INTRODUCTION: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent nivolumab in the second-line therapy of unresectable mesothelioma. METHODS: This was a cooperative group, single-arm, phase 2 trial enrolling patients with unresecta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudek, Arkadiusz Z., Xi, Min X., Scilla, Katherine A., Mamdani, Hirva, Creelan, Benjamin C., Saltos, Andreas, Tanvetyanon, Tawee, Chiappori, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689266/
https://www.ncbi.nlm.nih.gov/pubmed/38046376
http://dx.doi.org/10.1016/j.jtocrr.2023.100584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689266/
https://www.ncbi.nlm.nih.gov/pubmed/38046376
http://dx.doi.org/10.1016/j.jtocrr.2023.100584

Ejemplares similares